$BCDA
BioCardia, Inc. Stock $bcda

$bcda Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000143774920023294 Filed on November 10, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q3
Revenue	$50.00K	$34.00K	$194.0K
YoY Change	-77.27%	-82.47%	130.95%
Cost Of Revenue	$0.00	$0.00	$24.00K
YoY Change	-100.0%	-100.0%	-77.98%
Gross Profit	$50.00K	$34.00K	$170.0K
YoY Change	-72.22%	-80.0%	-780.0%
Gross Profit Margin	100.0%	100.0%	87.63%
Selling, General & Admin	$1.220M	$1.408M	$1.390M
YoY Change	-20.78%	1.29%	8.34%
% of Gross Profit	2440.0%	4141.18%	817.65%
Research & Development	$2.330M	$2.474M	$2.007M
YoY Change	7.37%	23.27%	-11.27%
% of Gross Profit	4660.0%	7276.47%	1180.59%
Depreciation & Amortization	$20.00K	$15.00K	$29.00K
YoY Change	-33.33%	-48.28%	31.82%
% of Gross Profit	40.0%	44.12%	17.06%
Operating Expenses	$3.550M	$3.882M	$3.397M
YoY Change	-4.31%	14.28%	-4.17%
Operating Profit	-$3.500M	-$3.848M	-$3.227M
YoY Change	-0.85%	19.24%	-9.61%
Interest Expense	$0.00	$1.000K	$112.0K
YoY Change	-100.0%	-99.11%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	-$565.0K
YoY Change		-100.0%	-2273.08%
Pretax Income	-$2.990M	-$3.850M	-$3.790M
YoY Change	-14.57%	1.58%	7.06%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.990M	-$3.848M	-$3.792M
YoY Change	-14.57%	1.48%	7.0%
Net Earnings / Revenue	-5980.0%	-11317.65%	-1954.64%
Basic Earnings Per Share
Diluted Earnings Per Share	-$224.8K	-$305.1K	-$628.5K
COMMON SHARES
Basic Shares Outstanding	12.43M		4.847M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.41M	$7.390M	$8.910M
YoY Change	283.01%	-17.06%	84.85%
Cash & Equivalents	$21.41M	$7.392M	$8.910M
Short-Term Investments
Other Short-Term Assets	$400.0K	$130.0K	$180.0K
YoY Change	-37.5%	-27.78%	-18.18%
Inventory			$45.00K
Prepaid Expenses
Receivables	$232.0K	$304.0K	$103.0K
Other Receivables	$620.0K	$770.0K	$0.00
Total Short-Term Assets	$22.66M	$8.590M	$9.237M
YoY Change	255.25%	-7.0%	72.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$145.0K	$161.0K	$210.0K
YoY Change	-19.89%	-23.33%	36.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$54.00K	$54.00K	$54.00K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$766.0K	$912.0K	$1.444M
YoY Change	-41.08%	-36.84%	594.23%
TOTAL ASSETS
Total Short-Term Assets	$22.66M	$8.590M	$9.237M
Total Long-Term Assets	$766.0K	$912.0K	$1.444M
Total Assets	$23.42M	$9.502M	$10.68M
YoY Change	205.08%	-11.04%	92.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$746.0K	$1.208M	$1.112M
YoY Change	-18.38%	8.63%	0.91%
Accrued Expenses	$87.00K	$105.0K	$102.0K
YoY Change	770.0%	2.94%	-54.87%
Deferred Revenue	$683.0K	$90.00K	$252.0K
YoY Change		-64.29%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$280.0K
YoY Change
Total Short-Term Liabilities	$4.248M	$4.320M	$4.044M
YoY Change	6.12%	6.82%	59.72%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$230.0K	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$840.0K	$1.440M
YoY Change	-100.0%	-41.67%	1700.0%
Total Long-Term Liabilities	$0.00	$1.070M	$1.440M
YoY Change	-100.0%	-25.69%	1700.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.248M	$4.320M	$4.044M
Total Long-Term Liabilities	$0.00	$1.070M	$1.440M
Total Liabilities	$4.248M	$5.389M	$5.487M
YoY Change	-19.97%	-1.79%	110.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$116.1M	-$113.1M	-$97.57M
YoY Change	14.85%	15.9%	17.95%
Common Stock	$16.00K	$12.00K	$46.00K
YoY Change	128.57%	-73.91%	21.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.18M	$4.113M	$5.194M
YoY Change
Total Liabilities & Shareholders Equity	$23.42M	$9.502M	$10.68M
YoY Change	205.08%	-11.04%	92.24%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$2.990M	-$3.848M	-$3.792M
YoY Change	-14.57%	1.48%	7.0%
Depreciation, Depletion And Amortization	$20.00K	$15.00K	$29.00K
YoY Change	-33.33%	-48.28%	31.82%
Cash From Operating Activities	-$3.420M	-$3.600M	-$1.470M
YoY Change	4.91%	144.9%	-26.87%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$20.00K	-$20.00K
YoY Change	-100.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$20.00K	-$20.00K
YoY Change	-100.0%	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	17.43M	-70.00K	9.890M
YoY Change	-25000.0%	-100.71%
NET CHANGE
Cash From Operating Activities	-3.420M	-3.600M	-1.470M
Cash From Investing Activities	0.000	-20.00K	-20.00K
Cash From Financing Activities	17.43M	-70.00K	9.890M
Net Change In Cash	14.01M	-3.690M	8.400M
YoY Change	-519.46%	-143.93%	-517.91%
FREE CASH FLOW
Cash From Operating Activities	-$3.420M	-$3.600M	-$1.470M
Capital Expenditures	$0.00	-$20.00K	-$20.00K
Free Cash Flow	-$3.420M	-$3.580M	-$1.450M
YoY Change	5.23%	146.9%	-27.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q3	bcda	Accrued Director Compensation Current AccruedDirectorCompensationCurrent
CY2019Q4	bcda	Accrued Director Compensation Current AccruedDirectorCompensationCurrent	648000
CY2020Q3	bcda	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	2236000
CY2019Q4	bcda	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	2561000
CY2020Q3	bcda	Accrued Salaries And Employee Benefits Current AccruedSalariesAndEmployeeBenefitsCurrent	843000
CY2019Q4	bcda	Accrued Salaries And Employee Benefits Current AccruedSalariesAndEmployeeBenefitsCurrent	652000
CY2020Q3	bcda	Accured Clinical Trial Costs AccuredClinicalTrialCosts	578000
CY2019Q4	bcda	Accured Clinical Trial Costs AccuredClinicalTrialCosts	519000
	bcda	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod
	bcda	Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
CY2020Q3	bcda	Grant Liability Current GrantLiabilityCurrent	620000
CY2019Q4	bcda	Grant Liability Current GrantLiabilityCurrent	630000
	bcda	Increase Decrease In Current Operating Lease Liability IncreaseDecreaseInCurrentOperatingLeaseLiability	64000
	bcda	Increase Decrease In Current Operating Lease Liability IncreaseDecreaseInCurrentOperatingLeaseLiability
	bcda	Increase Decrease In Non Current Operating Lease Liability IncreaseDecreaseInNonCurrentOperatingLeaseLiability	-453000
	bcda	Increase Decrease In Non Current Operating Lease Liability IncreaseDecreaseInNonCurrentOperatingLeaseLiability	-390000
	bcda	Issuance Of Restricted Stock Units In Lieu Of Cash Bonus2018 IssuanceOfRestrictedStockUnitsInLieuOfCashBonus2018
	bcda	Issuance Of Restricted Stock Units In Lieu Of Cash Bonus2018 IssuanceOfRestrictedStockUnitsInLieuOfCashBonus2018	165000
	bcda	Issuance Of Restricted Stock Units In Lieu Of Cash Bonus2019 IssuanceOfRestrictedStockUnitsInLieuOfCashBonus2019	391000
	bcda	Issuance Of Restricted Stock Units In Lieu Of Cash Bonus2019 IssuanceOfRestrictedStockUnitsInLieuOfCashBonus2019
	bcda	Issuance Of Restricted Stock Units In Lieu Of Cash Compensation IssuanceOfRestrictedStockUnitsInLieuOfCashCompensation	613000
	bcda	Issuance Of Restricted Stock Units In Lieu Of Cash Compensation IssuanceOfRestrictedStockUnitsInLieuOfCashCompensation
	bcda	Noncash Compensation Expense NoncashCompensationExpense	115000
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000925741
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12428794
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Registrant Name EntityRegistrantName	BioCardia, Inc.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	bcda
	bcda	Noncash Compensation Expense NoncashCompensationExpense
	bcda	Noncash Interest Expense Accretion To Loan Payable NoncashInterestExpenseAccretionToLoanPayable	2000
	bcda	Noncash Interest Expense Accretion To Loan Payable NoncashInterestExpenseAccretionToLoanPayable
	bcda	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	368000
	bcda	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	325000
	bcda	Payments Of Stock And Warrant Issuance Costs PaymentsOfStockAndWarrantIssuanceCosts
	bcda	Payments Of Stock And Warrant Issuance Costs PaymentsOfStockAndWarrantIssuanceCosts	1192000
CY2020Q3	bcda	Prepaid Expense And Other Current Assets PrepaidExpenseAndOtherCurrentAssets	132000
CY2019Q4	bcda	Prepaid Expense And Other Current Assets PrepaidExpenseAndOtherCurrentAssets	642000
	bcda	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants
	bcda	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	10452000
	bcda	Proceeds From Issuance Of Convertible Notes And Warrants ProceedsFromIssuanceOfConvertibleNotesAndWarrants
	bcda	Proceeds From Issuance Of Convertible Notes And Warrants ProceedsFromIssuanceOfConvertibleNotesAndWarrants	625000
CY2020Q1	bcda	Sharebased Compensation Arrangement By Sharebased Payment Award Remaining Weighted Average Award Vesting Period SharebasedCompensationArrangementBySharebasedPaymentAwardRemainingWeightedAverageAwardVestingPeriod	P3Y
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1208000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	914000
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	304000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	147000
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	105000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10000
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1008000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	957000
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	117186000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	103433000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	941000
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	655000
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	737000
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	690000
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	696000
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	756000
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1160000
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1192000
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	67000
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	412000
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	737000
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	756000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2333000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2142000
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	112000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3522820
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3310096
CY2020Q3	us-gaap	Assets Assets	9502000
CY2019Q4	us-gaap	Assets Assets	7678000
CY2020Q3	us-gaap	Assets Current AssetsCurrent	8590000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	6378000
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7392000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5585000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5585000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5358000
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7392000
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8910000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1807000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3552000
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.36
CY2020Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.36
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2435807
CY2020Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2435807
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12428794
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6825183
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12428794
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6825183
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	12000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	7000
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	90000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	102000
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	321000
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	3882000
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	3421000
	us-gaap	Costs And Expenses CostsAndExpenses	12130000
	us-gaap	Costs And Expenses CostsAndExpenses	11173000
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1
CY2019Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	691000
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	633000
CY2020Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	683000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt
CY2020Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2020Q3	us-gaap	Depreciation Depreciation	15000
	us-gaap	Depreciation Depreciation	52000
CY2019Q3	us-gaap	Depreciation Depreciation	29000
	us-gaap	Depreciation Depreciation	78000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	52000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	78000
CY2020Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet
CY2019Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	52000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	52000
CY2020Q3	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	762000
CY2019Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.13
CY2020Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0
CY2020Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	157000
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt
CY2019Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-521000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-521000
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	762000
	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	294000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	372000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	157000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-171000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	715000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	687000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-8000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8940000
CY2019Q3	us-gaap	Interest Expense InterestExpense	112000
	us-gaap	Interest Expense InterestExpense	2000
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	54000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	691000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-43000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-510000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-265000
CY2020Q3	us-gaap	Interest Expense InterestExpense	1000
	us-gaap	Interest Expense InterestExpense	112000
CY2020Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4000
CY2020Q3	us-gaap	Inventory Net InventoryNet
CY2019Q4	us-gaap	Inventory Net InventoryNet	4000
CY2020Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves
CY2020Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves
	us-gaap	Inventory Write Down InventoryWriteDown	3000
	us-gaap	Inventory Write Down InventoryWriteDown	54000
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	807000
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	649000
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	158000
CY2020Q3	us-gaap	Liabilities Liabilities	5389000
CY2019Q4	us-gaap	Liabilities Liabilities	5308000
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9502000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7678000
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4320000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4003000
CY2020Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	225000
CY2019Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10779000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9885000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-144000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6189000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-3848000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-3792000
	us-gaap	Net Income Loss NetIncomeLoss	-12015000
	us-gaap	Net Income Loss NetIncomeLoss	-11208000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4594000
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-565000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-530000
CY2020Q3	us-gaap	Notes Payable Current NotesPayableCurrent	284000
CY2019Q4	us-gaap	Notes Payable Current NotesPayableCurrent
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3848000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-3573000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3665000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-3750000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3227000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12031000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10678000
CY2020Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	150000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	451000
CY2019Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	150000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	450000
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	753000
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	592000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	528000
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	161000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	614000
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	158000
	us-gaap	Operating Lease Payments OperatingLeasePayments	473000
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	153000
	us-gaap	Operating Lease Payments OperatingLeasePayments	459000
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	697000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1065000
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1205
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y91D
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	54000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	54000
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000
CY2020Q3	us-gaap	Other Operating Income OtherOperatingIncome	1000
CY2019Q3	us-gaap	Other Operating Income OtherOperatingIncome	17000
	us-gaap	Other Operating Income OtherOperatingIncome	19000
	us-gaap	Other Operating Income OtherOperatingIncome	53000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1227000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	144000
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11500000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	506000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised
CY2020Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1169000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1138000
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	161000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	181000
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2474000
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2007000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7484000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6392000
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113085000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101070000
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	34000
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	194000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	99000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	495000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1505000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y219D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y219D
	us-gaap	Stock Issued1 StockIssued1	148000
	us-gaap	Stock Issued1 StockIssued1
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1408000
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1390000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4642000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4460000
	us-gaap	Share Based Compensation ShareBasedCompensation	2333000
	us-gaap	Share Based Compensation ShareBasedCompensation	2142000
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	574574
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.77
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	43083
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	515036
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	300432
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	821464
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1078813
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.99
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.04
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	13.19
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.32
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.15
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	569000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y146D
CY2019Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1206000
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10340000
CY2019Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9260000
CY2019Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	148000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	2370000
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-1283000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	7291000
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	4113000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	3792000
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	818000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	-2236000
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	5194000
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12618285
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6030662
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9059433
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5263058

Files In Submission

Name	View Source	Status
0001437749-20-023294-index-headers.html	Edgar Link	pending
0001437749-20-023294-index.html	Edgar Link	pending
0001437749-20-023294.txt	Edgar Link	pending
0001437749-20-023294-xbrl.zip	Edgar Link	pending
bcda-20200930.xml	Edgar Link	completed
bcda-20200930.xsd	Edgar Link	pending
bcda-20200930_cal.xml	Edgar Link	unprocessable
bcda-20200930_def.xml	Edgar Link	unprocessable
bcda-20200930_lab.xml	Edgar Link	unprocessable
bcda-20200930_pre.xml	Edgar Link	unprocessable
bcda20200930_10q.htm	Edgar Link	pending
ex_208376.htm	Edgar Link	pending
ex_208377.htm	Edgar Link	pending
ex_208378.htm	Edgar Link	pending
ex_208379.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCDA
BioCardia, Inc. Stock $bcda

2020 Q4 Form 10-Q Financial Statement

#000143774920023294 Filed on November 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCDA BioCardia, Inc. Stock $bcda

2020 Q4 Form 10-Q Financial Statement

#000143774920023294 Filed on November 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCDA
BioCardia, Inc. Stock $bcda